We searched PubMed, EMBASE, Cochrane database (CENTRAL), clinicaltrials.gov, and bibliographies for randomized controlled trials investigating the efficacy of antidepressant medications versus a non-treatment, placebo, or active treatment groups for depressive symptoms in PD. Twenty of 3191 retrieved studies (1893 patients) were included, but not all could be meta- 
| INTRODUCTION
Depression is a common neuropsychiatric disturbance in Parkinson's disease (PD), occurring in up to 35% of patients. 1 Although PD is diagnosed and staged based on its motor symptoms, non-motor symptoms like depression have been shown to have a greater adverse impact on health-related quality of life. [2] [3] [4] Depression in PD has been associated with greater disability, more rapid cognitive decline, higher rates of anxiety, increased mortality, and an increased burden on families and caregivers. [5] [6] [7] [8] Although the exact mechanisms are incompletely understood, both autopsy 9, 10 and functional connectivity 11 studies in PD patients show abnormalities in the limbic system and other areas of the brain associated with depression and the production of monoamines.
Derangements in the dopaminergic system may be even more relevant in PD depression than in depression in non-PD patients. 12, 13 Because this additional influence of dopaminergic denervation may represent a potential difference in pathophysiological mechanisms underlying depression in PD versus non-PD patients, treatment recommendations for depression in the non-PD population may not be generalizable to PD patients with depressive symptoms.
Treatments for depressive symptoms in PD have limited evidence for efficacy and tolerability, and there are no evidence-based guidelines to inform a "best" strategy for their use in clinical practice.
Previous systematic reviews have focused on specific classes of pharmacologic treatments for depression (eg, selective serotonin reuptake inhibitors [SSRIs] ). 14 The objective of this review is to conduct a systematic review and network meta-analysis comparing the efficacy and tolerability of all classes of antidepressant medications that have been tested in the PD population.
2 | METHODS
| Study and patient inclusion/exclusion criteria
This systematic review included all randomized controlled trials investigating any antidepressant medications for treatment of depressive symptoms in a study population with PD. We included studies in which antidepressant therapies were compared with other antidepressants (active control), placebo, or no therapy. Observational studies were excluded. We included studies, written in English, of adult (age 20
and older) patients with idiopathic PD (as defined by study original authors) and depressive symptoms. We did not include trials comparing antidepressants to cognitive/behavioral therapy because that was beyond the purview of our research question regarding the efficacy of antidepressant pharmacotherapies in PD. We excluded patients with juvenile PD, atypical parkinsonism, and secondary parkinsonism due to the likely differential response to pharmacotherapy. We included patients with dementia, which commonly co-occurs with mood disorders in PD, although several trials excluded these patients.
We excluded studies that explicitly excluded depressed PD patients.
For the purposes of the network meta-analysis, medications were clustered by antidepressant class in each "node" to compare class effects, which are generally viewed as fairly homogenous within a particular class. 15 To avoid publication bias, peer-reviewed journal publications, conference abstracts, and trials with outcomes reported in clinicaltrials.gov were all reviewed for inclusion.
| Search, selection, and extraction
We searched the Cochrane Central Register of Controlled Trials-CENTRAL in The Cochrane Library, Pubmed, EMBASE, and clinicaltrials.gov without any date or language restrictions. We used controlled vocabulary (MeSH and EMTREE) in addition to plain text searching (see Supplementary Material). We searched the reference lists of all included studies and relevant review articles using Web of Science. Two independent reviewers screened titles and abstracts then full text with discordance resolved through group consensus.
We reported the effect of each medication (and drug class) on depressive symptoms as a standardized mean difference (SMD) between groups to allow for comparison between various depression symptom severity scales. The primary time point for follow-up was 12 weeks, although we accepted measures between 4 and 24 weeks post-randomization.
To assess tolerability, the proportion of subjects experiencing discontinuation of intervention prior to trial completion in each study arm was compared using odds ratios with 95% confidence intervals.
Change in motor symptoms, as measured using the Unified Parkinson's Disease Rating Scale Part III (UPDRS III), was measured using a mean difference (95% CI). We assessed all included studies for any evidence that within-study missing data were not random. If missing data were not missing at random, differential between study arms, or common (eg, >20%), the study was labeled as high risk for attrition bias.
| Analytic methods
We analyzed classes of pharmacologic treatments separately because various mechanisms of action provide different degrees of efficacy in the non-PD literature. 16 records were reviewed, and 459 of these were retained for full text review after title/abstract screening. The most common reasons for exclusion at the full text screening phase were not evaluating a pharmacologic treatment for depression (n = 128) and not reporting depression or excluding patients with depression (n = 90; Figure 1 ).
Twenty randomized controlled trials published between 1988 and 2017 were included in this systematic review, 5 of which were abstracts (Table 1) .
| Participants
Sample sizes ranged from 12 to 669 participants and all included persons with PD, most of whom were 60 years and older recruited from neurological departments and outpatient PD clinics in Denmark, Italy, India, Romania, France, Canada, Puerto Rico, Brazil, the Netherlands, Spain, and the United States. The majority of trials reported an average duration of PD ranging from 3 to 8 years. Inclusion criteria for all studies included a diagnosis of PD and 14 studies required that participants meet criteria for depressive disorder.
FIGURE 1 Flow chart for systematic review study selection and screening 
| Interventions and comparisons
Twelve studies were 2-arm randomized trials; however, there were seven 3-arm trials [21] [22] [23] [24] [25] [26] [27] and one 7-arm trial. 28 The trials had a combination of no-treatment (n = 3), placebo (n = 12), and active treatment only comparison groups (n = 5 Fourteen of the included studies provided information on our secondary outcome, tolerability measured as adverse events, changes in motor symptoms, and treatment non-compliance or dropout.
Reporting of adverse events and side effects was inconsistent, so we analyzed treatment discontinuation as a measure of tolerability.
Changes in motor symptoms were consistently measured using the UPDRS.
| Risk of bias
The risk of bias summary and judgments by risk of bias domain is depicted in Figure 2 . Unclear risk of bias was common due to insufficient reporting of methods. Nine studies used random number sequence generation, and only 5 studies described specific methods of allocation. In 3 studies, participants were not blinded to intervention, 29, 30, 40 and assessors were un-masked in 2 studies. 30, 34 Ten studies described an intention-to-treat analysis such that all participants were analyzed as randomized. 21 
| Summary of systematic review
We found mixed efficacy of antidepressants. Eight studies [21] [22] [23] 26, 28, 36, 40, 41 concluded that antidepressants were more efficacious than placebo or control, 5 31, 33, 35, 37, 38 found no benefit of antidepressant therapy, 1 concluded that a tricyclic was efficacious but an SSRI was not, 25 and 1 abstract did not have interpretable results. 24 The instruments used to assess depressive symptoms and differences in data reporting were important sources of methodological heterogeneity. PD and depression eligibility criteria were similar across studies that reported this information. Four studies included participants with dementia, 24, 27, 34, 39 in whom antidepressants have been shown to be less effective, thereby potentially modifying treatment effects. 42, 43 Differences in study design and outcome measurement contributed to methodological heterogeneity. The majority of studies were individual randomized-controlled trials; however, one of the included studies was a randomized crossover design. 36 Each depression scale has its own sensitivity, specificity, and sensitivity to longitudinal change. 43 While the majority of studies included a placebo comparison group (see Table 1 ), 3 included a no-treatment control group, and 5 only included active study arms. Research on the placebo effect has found some therapeutic benefit of placebos in placebo-control groups that are blind to study assignment in randomized trials of antidepressants. 44 Thus, we might expect the effect size for trials employing a placebo group blind to study assignment to be smaller relative to trials employing a no-treatment control group.
3.3 | Meta-analyses and network meta-analysis
| Effect of treatment on depression
Standardized mean differences between active and control groups were calculated in 5 studies 25, 26, 33, 38, 40 stratified by drug class (Figure 3 ). At the individual study level 3 studies reported significant intervention effects favoring MAOIs, SNRIs, SSRIs, and tricyclics over placebo. 25, 26, 38 The 2 remaining SSRI versus placebo conditions 25, 33 and 1 SARI (trazodone) versus placebo condition 40 found no significant differences.
In a subgroup analysis comparing the SMD between SSRI and pla- To assess the relative efficacy of these drug classes and the comparison groups, we conducted a network meta-analysis to allow for direct and indirect comparisons to contribute to the estimation of all pairwise comparisons of treatment effects. As shown in the network map (Figure 4) , the most common comparisons were between SSRIs and placebo. The League Table (Table 2) influences compliance and quality of life, and compliance was reasonably good in the 11 trials that reported discontinuation rates. Also problematic is the definition of "depression" or "depressive symptoms"
in PD and the overlap with cognitive impairment, apathy, and behavioral disturbances. We acknowledge that considerable heterogeneity in the definition of depression exists among these studies and the relationship between treatment-associated changes in depression rating scales and related symptoms such as cognitive dysfunction and apathy could not be assessed given the available data in these trials. Use of a mixed effects rather than fixed effects meta-analysis accounts for some of this variability in patient populations between studies.
Risk of bias risk was assessed as "unclear" for many of the domains we examined in most studies (Figure 2 ). In the 5 studies included in the meta-analysis, only 2 studies were categorized as "high" risk of bias in any domain. 33 Across studies, we found a slight asymmetry in the distribution of effects (Supplementary Material Figure 2 ), suggesting that publication bias may be present. This may be due to the inability to obtain outcomes data from several abstracts despite attempted contact with the authors.
Our findings are consistent with previous reviews evaluating the effect of antidepressants in PD, although our study includes more antidepressant drug classes. 14, 45 One of these reviews focused on SSRIs, 14 while the other included non-pharmacologic and non-antidepressant pharmacologic treatments for depression. 45 A previous network meta-analysis found that TCAs had a larger effect than SSRIs on depression, 46 and while our analysis trended in that direction, it was not significant (TCA vs SSRI 0.28, 95%CI: −0.46, 1.03). That study also did not include other antidepressant classes that were included in our network meta-analysis, such as SARIs (trazodone and nefazodne) or
MAOIs (safinamide, rasagaline), but did compare SSRIs, SNRIs, and 
MAOI
Negative favors the column, positive favors the row; bold indicates significant difference from the null (zero).
Abbreviations: MAOI, monoamine oxidase inhibitor; SARI, serotonin antagonist and reuptake inhibitor; SNRI, serotonin-norepinephrine reuptake inhibitor; SSRI, serotonin-specific reuptake inhibitor.
TCAs dopamine agonists including pramipexole and pergolide. 46 Overall, our analysis was restricted to classes of medications considered to 
